anonymous
Guest
anonymous
Guest
Merck is hell-bent on becoming a major player in the lucrative immune-oncology space as its blockbuster cancer drug Keytruda met its goal of extending the lifespan of cancer patients. https://news.alphastreet.com/merck-...-rivals-with-positive-keytruda-trial-results/